Prostadir

A drug created and manufactured by Advancer Enterprises, it entered Advancer's pharmaceutical catalog in late YE 45. Prostadir is a complex, broad-spectrum organ-regenerative medicine that aids in the recovery and regeneration of various organ tissues.

The development of Prostadir was motivated by the increasing prevalence of organ-specific diseases and the limitations of existing treatments. Advancer Enterprises, committed to pushing the boundaries of medical science, initiated an ambitious project to create a drug that could not only treat but regenerate damaged organs. The project involved extensive research in cellular biology, pharmacology, and regenerative medicine. After years of meticulous research and clinical trials, Prostadir was finally submitted for Imperial approval in late YE 45.

Prostadir operates at a cellular level, activating stem cells and directing them to replace damaged or diseased cells in targeted organs. Its broad-spectrum applicability makes it a versatile treatment option for a variety of organs, including the heart, liver, kidneys, and lungs. The drug also stimulates the production of essential proteins and growth factors, further enhancing its regenerative capabilities. The standard dosage for Prostadir is 100 mg, administered intravenously once a week for a duration of 4 to 6 weeks.

Prostadir is generally well-tolerated, but it can induce mild flu-like symptoms such as fatigue, fever, and muscle aches. These symptoms are often transient and serve as an indicator that the body is responding to the treatment. However, in rare instances, Prostadir may trigger an immune response, leading to inflammation and potentially severe complications. Patients undergoing treatment with Prostadir should be closely monitored for any signs of an adverse immune reaction.

An overdose of Prostadir poses a significant risk of uncontrolled cell growth, thereby elevating the risk of cancerous formations. The threshold for overdose is estimated to be 250 mg within a single administration, which is 2.5 times the recommended dosage. Immediate medical intervention is crucial, including diagnostic tests for abnormal cell growth and, if required, initiation of chemotherapy.

Demibear created this article on 2023/10/09 23:33.

Approval Thread: https://stararmy.com/roleplay-forum/threads/advancer-enterprises-white-lion-type-45-vehicle-aid-kit.71051/